LRH-1 is a novel regulator of neutrophil-driven immune responses within the tumor microenvironment
Authors:
- Yu WangYWYu Wang
- Bryan DuongBDBryan Duong
- Sam KeeleySKSam Keeley
- Natalia KrawczynskaNKNatalia Krawczynska
- Shruti V. BendreSBShruti V. Bendre
- Claire P. SchaneCSClaire P. Schane
- Erin WeisserEWErin Weisser
- Nadia Cobo VuilleumierNVNadia Cobo Vuilleumier
- Lara KockayaLKLara Kockaya
- Yifan FeiYFYifan Fei
- Anasuya Das GuptaAGAnasuya Das Gupta
- Hashni Epa Vidana GamageHGHashni Epa Vidana Gamage
Preprint
Abstract
Elevated plasma cholesterol levels have been linked to worse outcomes in breast and ovarian cancer. Prior work including our own has demonstrated that myeloid immune cells are highly responsive to cholesterol fluctuations and to proteins involved in cholesterol regulation. However, the specific roles of Liver Receptor Homolog-1 (LRH-1, or NR5A2), a key transcriptional regulator of cholesterol homeostasis, within myeloid cells remains largely undefined. Interestingly, LRH-1 mRNA levels are reduced in both breast and ovarian tumors compared to normal tissue. Its elevated expression within tumors is associated with increased survival time. These clinical correlations prompted us to explore the role of LRH-1 in myeloid cells particularly in the context of breast and ovarian cancer progression. Initial analyses confirmed LRH-1 expression in various myeloid cell types, with particularly high levels in neutrophils. We therefore focused on how LRH-1 influences neutrophil behaviors relevant to cancer, including migration, NETosis, phagocytosis, and interactions with T cells. Small molecule ligands for LRH-1 regulated neutrophil migration towards cancer cells. Phagocytosis was also regulated by LRH-1 small molecule ligands, the extent being dependent on type of bait ( e. coli vs. cancer cells). In T cell co-cultures, neutrophils pretreated with an LRH-1 agonist promoted greater T cell expansion - particularly in CD4⁺ cells - while LRH-1 inhibition suppressed this response. Moreover, LRH-1 activation reduced NETosis, while treatment with an antagonist or inverse agonist enhanced NETosis. Treatment of mice with an inverse agonist of LRH-1 increased the growth of 4T1 and E0771 mammary tumors. Given prior evidence that neutrophils contribute to the recurrence of dormant lesions, we further examined the role of LRH-1 in this context. Mice harboring dormant D2.0R mammary cancer lesions treated with an LRH-1 inverse agonist exhibited earlier tumor recurrence and enhanced metastatic progression compared to vehicle-treated controls. In contrast, treatment with BL001, a small chemical LRH-1 agonist, delayed recurrence in D2.0R-grafted mice. Collectively, these findings reveal that LRH-1 is a novel regulator of neutrophil-driven immune responses within the tumor microenvironment. LRH-1 thus remerges as a promising therapeutic target to suppress metastasis or prevent recurrence in breast cancer.Keywords
Funding Information
- Department of Defense, CDMRP, Breast Cancer Research Program (BC241117/HT9425-25-1-0285)
- Department of Defense, CDMRP, Breast Cancer Research Program (BC200206/W81XWH-20-BCRP-EOHS)
- Vencer el Cancer
- DiabetesCero Foundation
- Breakthrough T1D, formerly Juvenile Diabetes Research Foundation (2-SRA-2019-837-S-B)
- Breakthrough T1D, formerly Juvenile Diabetes Research Foundation (3-SRA-2023-1307-S-B)
- Endocrine Society (Research Experiences for Graduate and Medical Students Award)
- Cancer Center at Illinois (Graduate Cancer Scholarship Program Award)
- Beckman Institute for Advanced Science and Technology (Postdoctoral Fellows Program)
- University of Illinois
This publication has 97 references indexed in Scilit:
- LRH‐1/NR5A2 targets mitochondrial dynamics to reprogram type 1 diabetes macrophages and dendritic cells into an immune tolerance phenotypeClinical and Translational Medicine, 2024
- Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumorsCancer and Metastasis Reviews, 2023
- The nuclear receptor TLX (NR2E1) inhibits growth and progression of triple- negative breast cancerBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2022
- Our evolving understanding of how 27-hydroxycholesterol influences cancerBiochemical Pharmacology, 2022
- 27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progressionCancer Letters, 2020
- Nuclear Receptors: A Historical Perspective2019
- Immune Checkpoint Blockade for Breast Cancer2018
- EMT, cell plasticity and metastasisCancer and Metastasis Reviews, 2016
- Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancerTumor Biology, 2015
- The biology and clinical implications of prostate cancer dormancy and metastasisJournal of Molecular Medicine, 2015